Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Resverlogix Corporation
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- RVX Therapeutics Inc. (now Zenith Epigenetics Corp.)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.